Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from ATAI Life Sciences ( (ATAI) ).
On November 5, 2025, Atai Beckley N.V. filed a prospectus supplement with the SEC related to the resale of 5,316,238 common shares. This action is part of fulfilling registration rights granted during the acquisition of Beckley Psytech Limited, impacting the company’s share distribution and potentially its market standing.
The most recent analyst rating on (ATAI) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.
Spark’s Take on ATAI Stock
According to Spark, TipRanks’ AI Analyst, ATAI is a Neutral.
ATAI Life Sciences’ overall stock score is primarily impacted by its weak financial performance, characterized by ongoing losses and negative cash flows. While technical analysis shows some positive momentum, the valuation remains unattractive due to a negative P/E ratio and lack of dividends. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on ATAI stock, click here.
More about ATAI Life Sciences
Average Trading Volume: 6,007,085
Technical Sentiment Signal: Buy
Current Market Cap: $1.38B
See more data about ATAI stock on TipRanks’ Stock Analysis page.